Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin - PubMed (original) (raw)
Comparative Study
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
Patrizia Castellani et al. Am J Pathol. 2002 Nov.
Abstract
Different fibronectin (FN) isoforms are generated by the alternative splicing of the primary FN transcript. We previously demonstrated that the isoform containing the extra domain B sequence of fibronectin (B-FN), a complete type-III-homology repeat, is a marker of angiogenesis that accumulates around neovasculature only during angiogenic processes. We produced a single-chain human recombinant antibody (scFv), L19, which reacts specifically with B-FN and selectively targets tumor vasculature in vivo. We used this scFv and an antibody against a pan-endothelial marker (Factor VIII) in a double-staining procedure on specimens of low- and high-grade astrocytomas to determine the percentage of B-FN-positive vessels, (denominating the resulting value angiogenic index [AI]). Compared to vascular density and proliferative activity (evaluated using antibodies to Factor VIII and Ki67, respectively), AI correlated better with tumor grade (1.6 +/- 2.6% and 92.0 +/- 8.7% of B-FN-positive vessels in low- and high-grade astrocytomas, respectively) and was a more precise diagnostic tool than either of the two conventional methods. In fact, discriminating analysis using these three parameters showed that only AI accurately classified 100% of the cases studied, compared to 64% and 89% correctly diagnosed by vascular density and of proliferating cells, respectively.
Figures
Figure 1.
Serial sections of a glioblastoma (A and B), normal brain (C and D), and a pilocytic astrocytoma (E and F) stained with the scFv L-19 specific for B-FN (A, C, E) and with the anti-factor VIII mAb (B, D, F). Scale bars, 10 μm.
Figure 2.
Serial sections of a anaplastic astrocytoma showing neoplastic and normal tissue (A and B) stained with the anti-factor VIII mAb and with scFv L-19, respectively. Only the vessels within the tumors were stained by the scFv L-19. Two different magnifications (C and D) of a glioblastoma multiforme specimen showing neoplastic and normal tissue double stained with the scFv L-19 (brown) and with anti-factor VIII mAb (red). Two different magnifications (E and F) of an in situ hybridization experiment using human glioblastoma cryostat sections with the DIG-labeled cRNA ED-B repeat probe. A positive signal was visible in the endothelial cells. Scale bars, 10 μm.
Figure 3.
Left: Number of Ki-67-positive cells calculated in five different areas of each specimen of high- and low-grade astrocytomas using the mAb specific for proliferating cells. Middle: Number of vessels calculated in five different areas of each specimen of high- and low-grade astrocytomas using the mAb anti-factor VIII. Right: Percentage of B-FN-positive vessels calculated in five different areas of each specimen of high- and low-grade astrocytomas double stained using the scFv L-19 and the mAb anti-factor VIII. Although considerable overlapping of the results of high- and low-grade astrocytomas for proliferating cells and vascular density was observed, no overlapping was seen when measuring the percentage of B-FN-positive vessels.
Similar articles
- The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.
Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. Castellani P, et al. Int J Cancer. 1994 Dec 1;59(5):612-8. doi: 10.1002/ijc.2910590507. Int J Cancer. 1994. PMID: 7525495 - Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors.
Birchler MT, Milisavlijevic D, Pfaltz M, Neri D, Odermatt B, Schmid S, Stoeckli SJ. Birchler MT, et al. Laryngoscope. 2003 Jul;113(7):1231-7. doi: 10.1097/00005537-200307000-00023. Laryngoscope. 2003. PMID: 12838025 - Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8.
Ventura E, Sassi F, Parodi A, Balza E, Borsi L, Castellani P, Carnemolla B, Zardi L. Ventura E, et al. PLoS One. 2010 Feb 10;5(2):e9145. doi: 10.1371/journal.pone.0009145. PLoS One. 2010. PMID: 20161770 Free PMC article. - 99mTc-Anti-ED-B fibronectin single-chain antibody fragment L19-His.
Cheng KT. Cheng KT. 2007 Feb 12 [updated 2008 Jan 16]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Feb 12 [updated 2008 Jan 16]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641593 Free Books & Documents. Review. - 76Br-Human recombinant anti-ED-B fibronectin L19-small immunoprotein.
The MICAD Research Team. The MICAD Research Team. 2007 Aug 4 [updated 2007 Aug 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2007 Aug 4 [updated 2007 Aug 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641744 Free Books & Documents. Review.
Cited by
- The impact of inflammation and acute phase activation in cancer cachexia.
Robinson TP, Hamidi T, Counts B, Guttridge DC, Ostrowski MC, Zimmers TA, Koniaris LG. Robinson TP, et al. Front Immunol. 2023 Oct 31;14:1207746. doi: 10.3389/fimmu.2023.1207746. eCollection 2023. Front Immunol. 2023. PMID: 38022578 Free PMC article. Review. - Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin.
Zhang Z, Liu C, Wang M, Sun R, Yang Z, Hua Z, Wu Y, Wu M, Wang H, Qiu W, Yin H, Yang M. Zhang Z, et al. J Immunother Cancer. 2023 Aug;11(8):e007199. doi: 10.1136/jitc-2023-007199. J Immunother Cancer. 2023. PMID: 37586774 Free PMC article. - Nucleic acid drug vectors for diagnosis and treatment of brain diseases.
Lu ZG, Shen J, Yang J, Wang JW, Zhao RC, Zhang TL, Guo J, Zhang X. Lu ZG, et al. Signal Transduct Target Ther. 2023 Jan 17;8(1):39. doi: 10.1038/s41392-022-01298-z. Signal Transduct Target Ther. 2023. PMID: 36650130 Free PMC article. Review. - CAR-T-Cell Therapy for Solid Tumors Positive for Fibronectin Extra Domain B.
Zhang Z, Liu C, Yang Z, Yin H. Zhang Z, et al. Cells. 2022 Sep 14;11(18):2863. doi: 10.3390/cells11182863. Cells. 2022. PMID: 36139437 Free PMC article. - Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT, Marquette K, Chang CB, Golas J, Jain S, Lam MH, Guffroy M, Leal M, Falahatpisheh H, Mathur D, Chen T, Kelleher K, Khandke K, Muszynska E, Loganzo F, Rosfjord E, Lucas J, Kan Z, Subramanyam C, O'Donnell C, Neri D, Gerber HP, May C, Sapra P. Hooper AT, et al. Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472. doi: 10.1158/1535-7163.MCT-22-0099. Mol Cancer Ther. 2022. PMID: 35793468 Free PMC article.
References
- Van Den Hoff A: Stromal involvement in malignant growth. Adv Cancer Res 1988, 50:159-196 - PubMed
- Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1998, 86:353-564 - PubMed
- Castellani P, Viale G, Dorcaratto A, Nicolò G, Kaczmarek J, Querzè G, Zardi L: The fibronectin isoform containing ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994, 59:612-618 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous